moclobemide has been researched along with Depression, Endogenous in 216 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders." | 9.10 | Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. ( Amador, XF; Baldini Rossi, N; Cassano, GB; Cassano, P; Dell'Osso, L; Pini, S; Savino, M, 2003) |
| "The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder." | 9.08 | Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. ( Annable, L; Beauclair, L; Bland, R; Chouinard, G; Ingram, P; Joffe, R; Kennedy, S; Lapierre, YD; McKenna, K; Reesal, R; Rickhi, BG, 1997) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 9.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| "A double-blind comparison of moclobemide and toloxatone was performed in adult out-patients diagnosed as suffering from a major depressive disorder." | 9.07 | A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder. ( Lemoine, P; Mirabaud, C, 1992) |
| "N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively." | 9.06 | Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. ( Becker, T; Beckmann, H; Classen, W; Laux, G; Lesch, KP; Riederer, P; Sofic, E; Struck, M, 1990) |
| " He developed severe pseudohallucinations under a treatment with moclobemide." | 7.73 | Pseudohallucinations associated with moclobemide: a case report. ( Degner, D; Grohmann, R; Kropp, S; Porzig, J; Rüther, E, 2005) |
| "The urinary excretion rates of norepinephrine were assayed in 26 patients diagnosed as major depressive disorders (primary, unipolar), before and after 14 days of treatment with the monoamine oxidase inhibitor Moclobemide (Ro 11-1163)." | 7.67 | High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163). ( Barbeito, L; Dajas, F; Lista, A, 1984) |
| " No adverse effects were noted." | 6.69 | Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. ( Achiron, A; Barak, Y; Ur, E, 1999) |
| " Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients." | 6.67 | Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria. ( Baumhackl, U; Gallhofer, B; Geretsegger, C; Hebenstreit, GF; Loidl, M; Radmayr, E; Saletu, M; Schöny, W; Stabl, M, 1990) |
| "Moclobemide appears to be a well tolerated antidepressant without the liability to produce significant postural hypotension and without the need for a tyramine-poor diet." | 6.67 | A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. ( Fraser, AR; Menkes, DB; Mullen, PE; Newburn, GM, 1990) |
| "Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery." | 6.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| "To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders." | 5.10 | Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. ( Amador, XF; Baldini Rossi, N; Cassano, GB; Cassano, P; Dell'Osso, L; Pini, S; Savino, M, 2003) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 5.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| "Moclobemide was shown to be a safe, well tolerated and effective antidepressant, which did not cause impairment of cognitive function in elderly patients with a DSM-III diagnosis of dementia and/or DSM-III major depression." | 5.08 | Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. ( Amrein, R; Mountjoy, CQ; Roth, M, 1996) |
| "The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder." | 5.08 | Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. ( Annable, L; Beauclair, L; Bland, R; Chouinard, G; Ingram, P; Joffe, R; Kennedy, S; Lapierre, YD; McKenna, K; Reesal, R; Rickhi, BG, 1997) |
| "A double-blind comparison of moclobemide and toloxatone was performed in adult out-patients diagnosed as suffering from a major depressive disorder." | 5.07 | A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder. ( Lemoine, P; Mirabaud, C, 1992) |
| "13 patients with major depressive disorder, who responded well to the reversible MAO-A-inhibitor moclobemide after unsuccessful initial treatment with tri- or tetracyclic antidepressants were monitored under naturalistic outpatient therapy conditions with moclobemide plasma level control for an average of 7." | 5.06 | [Moclobemide in the long-term treatment of depressed patients]. ( Carl, G; Laux, G, 1989) |
| "N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively." | 5.06 | Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. ( Becker, T; Beckmann, H; Classen, W; Laux, G; Lesch, KP; Riederer, P; Sofic, E; Struck, M, 1990) |
| " Thirty-eight patients with episodic, chronic and atypical depressive disorder (DSM-III) were equally randomized to 6 weeks' treatment with either three daily doses of 100 mg moclobemide or 50 mg clomipramine." | 5.05 | Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial. ( Holm, P; Larsen, JK; Mikkelsen, PL, 1984) |
| "Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders." | 4.82 | Moclobemide: therapeutic use and clinical studies. ( Bonnet, U, 2003) |
| "Moclobemide is a reversible monoamine oxidase inhibitor (MAOI) which preferentially inhibits type-A MAO." | 3.76 | Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. ( Amrein, R; Biziére, K; Schmid-Burgk, W; Stabl, M, 1989) |
| " He developed severe pseudohallucinations under a treatment with moclobemide." | 3.73 | Pseudohallucinations associated with moclobemide: a case report. ( Degner, D; Grohmann, R; Kropp, S; Porzig, J; Rüther, E, 2005) |
| "Five patients with depressive disorder who experienced sexual side effects during treatment with standard doses of fluoxetine (20 to 40 mg per day)." | 3.70 | Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression. ( Ramasubbu, R, 1999) |
| " The purpose of this report is to evaluate disturbances in sexual drive/desire and arousal/orgasm in 107 patients who met criteria for major depressive disorder and received treatment with either moclobemide, paroxetine, sertraline, or venlafaxine." | 3.70 | Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. ( Bacchiochi, JR; Bagby, RM; Dickens, SE; Eisfeld, BS; Kennedy, SH, 2000) |
| " the norepinephrine reuptake inhibitor maprotiline (MAP) on alpha 2-adrenoceptor responsivity was studied by clonidine (CLON)-evoked growth hormone (GH) release in major depressive disorder." | 3.68 | Alpha 2-adrenoceptor responsivity in depression: effect of chronic treatment with moclobemide, a selective MAO-A-inhibitor, versus maprotiline. ( Laux, G; Lesch, KP; Mueller, T, 1990) |
| "The urinary excretion rates of norepinephrine were assayed in 26 patients diagnosed as major depressive disorders (primary, unipolar), before and after 14 days of treatment with the monoamine oxidase inhibitor Moclobemide (Ro 11-1163)." | 3.67 | High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163). ( Barbeito, L; Dajas, F; Lista, A, 1984) |
| "Chronic fatigue syndrome is characterized by prolonged and disabling fatigue and a range of neuropsychiatric symptoms including depressed and/or irritable mood." | 2.69 | A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. ( Bennett, BK; Hickie, IB; Lloyd, AR; Wakefield, D; Wilson, AJ; Wright, JM, 2000) |
| " No adverse effects were noted." | 2.69 | Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. ( Achiron, A; Barak, Y; Ur, E, 1999) |
| " Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not." | 2.68 | Moclobemide versus fluoxetine for a major depressive episode. ( Haazen, L; Janne, P; Mirel, J; Parent, M; Reynaert, C, 1995) |
| " It was necessary to adjust nortriptyline dosage in < 20% of patients to maintain serum levels within the postulated therapeutic window of 50-170 ng/ml." | 2.68 | Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. ( Amin, M; Holm, P; Katona, C; Klitgaard, N; Kragh-Sørensen, P; Kühn, H; Leek, CA; Nair, NP; Ng Ying Kin, NM; Stage, KB, 1995) |
| "The pharmacokinetic variability of moclobemide, a new short half-life reversible selective inhibitor of monoamine oxidase (MAO) was investigated through analysis of concentrations measured during early open clinical use." | 2.68 | Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. ( Balant, LP; Balant-Gorgia, AE; Gex-Fabry, M, 1995) |
| " The results indicated that all doses were safe with no evidence of significant changes in laboratory values or cardiovascular parameters." | 2.68 | Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials. ( Plenker, A; Püchler, K; Volz, HP, 1997) |
| " This applies particularly to the utilization of the recommended dosage range, especially in severely depressed states, and the consistent, syndrome-based combination treatment with hypnotics/sedatives or neuroleptics in the respective patient groups indicated." | 2.68 | Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide. ( Baier, D; Laux, G, 1997) |
| "This was an open study of moclobemide, 300 to 450 mg daily, as continuation treatment for 18 weeks, after a 6-week randomized, double-blind acute treatment period with moclobemide administered in three different dosage regimens." | 2.68 | Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months. ( de Kock, RF; Gagiano, CA; Müller, FG; Schall, R, 1995) |
| "The data on a twice-daily dosage schedule with moclobemide in the treatment of a major depressive episode (MDE) is limited." | 2.68 | Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules. ( Berk, M; Brown, RG; Gagiano, CA; Joubert, PM; Müller, FG; Schall, R, 1995) |
| " We studied the efficacy and adverse effects of moclobemide in patients with chronic fatigue syndrome, stratifying the sample both by co-morbid major depressive illness and by sleep disturbance." | 2.68 | An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. ( Cleary, KJ; White, PD, 1997) |
| " The efficacies between the two dosing regimens as determined by the HAM-D score and from the CGI were found not to differ significantly." | 2.68 | A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R) ( Caracatsanis, A; Collier, J; Collins, C; Cramer, D; Edwards, R; Fox, K; Newburn, G; Reeves, J; Thomas, H, 1995) |
| "Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) with selectivity for the MAO type A isoenzyme." | 2.68 | A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. ( Kok, LP; Tsoi, WF, 1995) |
| " There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common." | 2.68 | Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. ( Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996) |
| " Adverse events during this long-term treatment were also compared with those of a subgroup of these patients who, before long-term treatment, were treated on a short-term basis (n = 706)." | 2.67 | Safety and efficacy during long-term treatment with moclobemide. ( Amrein, R; Moll, E; Neumann, N; Schmid-Burgk, W; Stabl, M, 1994) |
| "Imipramine-treated patients reported more anticholinergic side effects, whereas tiredness and headache were observed more frequently in the moclobemide-treated patients." | 2.67 | Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study. ( Jääskeläinen, J; Kaartinen, P; Kalli, A; Kilponen, E; Koskinen, T; Nikkilä, H; Pirttiperä, V; Rimón, R; Seppälä, J, 1993) |
| "Moclobemide was compared with amitriptyline for antidepressant efficacy, safety and tolerance." | 2.67 | Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium. ( Beckers, G; Berger, M; de Bleeker, E; Faidherbe, J; Hellstern, K; Jaunes, C; Sieben, G; Vereecken, A; Ward, J; Wolfrum, C, 1990) |
| "Moclobemide was compared to placebo in two parallel groups of depressed patients, in a multicenter randomized, double-blind study of six weeks treatment duration." | 2.67 | Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. ( Botte, L; Evrard, JL; Gilles, C; Stenier, P; Wolfrum, C, 1992) |
| "Moclobemide is a well-tolerated medication at therapeutic doses; it is globally as effective as amitriptyline in the treatment of major depression." | 2.67 | A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. ( Alda, M; Bakish, D; Ellis, J; Lapierre, Y; Wiens, A, 1992) |
| "Moclobemide is a specific monoamine oxidase-A inhibitor which does not bind irreversibly to the enzyme, unlike the currently available MAOIs." | 2.67 | An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression. ( Adena, M; Evans, L; George, T; Johnson, G; Mitchell, P; O'Sullivan, B, 1992) |
| "Moclobemide was compared with isocarboxazide and clomipramine in patients with depression." | 2.67 | Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. ( Anderson, J; Bille, A; Christensen, EM; Gjerris, A; Holm, P; Høyer, E; Jensen, H; Langagergaard, A; Larsen, JK; Mejlhede, A, 1991) |
| "Moclobemide was as effective as Fluvoxamine but much better tolerated as shown by a lower incidence of side effects such as gastrointestinal problems or headache." | 2.67 | [Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes]. ( Barrelet, L; Blajev, B; Bolzani, L; de Saussure, C; Gachoud, JP; Kasas, A; Van, H, 1991) |
| "Moclobemide appears to be a well tolerated antidepressant without the liability to produce significant postural hypotension and without the need for a tyramine-poor diet." | 2.67 | A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. ( Fraser, AR; Menkes, DB; Mullen, PE; Newburn, GM, 1990) |
| " Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients." | 2.67 | Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria. ( Baumhackl, U; Gallhofer, B; Geretsegger, C; Hebenstreit, GF; Loidl, M; Radmayr, E; Saletu, M; Schöny, W; Stabl, M, 1990) |
| "Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited." | 2.67 | Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules. ( Bodemer, W; Gagiano, CA; Hart, GA; Schall, R, 1994) |
| "Moclobemide was the better-tolerated drug, producing fewer side effects than maprotiline did: in particular, fewer instances of somnolence and dry mouth." | 2.67 | Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners. ( Dick, P; Gachoud, JP; Köhler, M, 1994) |
| "Moclobemide was compared with placebo for antidepressant activity, tolerance and safety in 2 parallel groups of 23 and 24 depressed patients." | 2.67 | Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium. ( Berger, M; Botte, L; Evrard, JL; Gilles, C; Hellstern, K; Mesters, P; Ward, J; Wolfrum, C, 1990) |
| "Moclobemide was compared with desipramine in 30 patients with endogenous depression." | 2.67 | Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression. ( Gabelic, I; Moll, E, 1990) |
| "Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression." | 2.67 | Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany. ( Funke, HJ; Hellstern, K; Malanowski, H; Moritz, E, 1990) |
| "Patients with endogenous depression responded better to clomipramine, whereas nonendogenous disorders did better on moclobemide." | 2.67 | Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. ( Berger, M; Burton, P; Cattiez, P; Defleur, J; Dierick, M; Franck, G; Hellstern, K; Hermans, W; Roelandts, A; Wolfrum, C, 1990) |
| "Imipramine (25 patients) was given in a dosage starting with 33 mg and gradually increased to 100 mg/day in the first 5 days, after which it could be further increased; 25 patients received placebo." | 2.67 | Moclobemide, imipramine and placebo in the treatment of major depression. ( Alves, A; Mundim, FD; Nardi, AE; Schmid-Burgk, W; Versiani, M, 1990) |
| " The dosage was 150-300 mg moclobemide and 15-30 mg tranylcypromine daily." | 2.67 | Moclobemide versus tranylcypromine in the treatment of depression. ( Moll, E; Rossel, L, 1990) |
| " A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability." | 2.67 | Moclobemide versus fluoxetine for major depressive episodes. ( Bruynooghe, F; De Cuyper, H; Demeulemeester, F; Geerts, S; Haazen, L, 1994) |
| " Side effects were assessed through the Dosage Record Emergent Symptoms at days 0, 7, 14, 30, 45, and 60." | 2.67 | Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine. ( Delle Chiaie, R; Donnini, M; Gambino, C; Pancheri, P; Seripa, S; Trillo, L; Vicario, E, 1994) |
| "Moclobemide was superior to imipramine in mean time to onset of effect (7." | 2.66 | A comparison of moclobemide and imipramine in treatment of depression. ( Casacchia, M; Rossi, A, 1989) |
| "Diazepam was a significantly better antidepressant than moclobemide at four week, although not at eight weeks." | 2.66 | Is diazepam an antidepressant? ( Davis, B; Maguire, KP; Schweitzer, I; Tiller, JW, 1989) |
| "Moclobemide proved to be a well-tolerated and effective antidepressant, with both groups showing improvement." | 2.66 | A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion. ( Böning, J; Fuchs, G; Lensch, K; Milech, U, 1987) |
| "treated with Moclobemide and from 36." | 2.65 | A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. ( Barba, C; Carolei, A; Casacchia, M; Frontoni, M; Meco, G; Rossi, A; Zylberman, MR, 1984) |
| "Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery." | 2.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| "Moclobemide was first hypothesized as being an antilipaemic or antibiotic, but the screenings were negative." | 2.39 | Moclobemide: a paradigm of research in clinical psychopharmacology. ( Amrein, R; Angst, J; Stabl, M, 1996) |
| "Moclobemide is a reversible and selective inhibitor of monoamine oxidase subtype A with a wide spectrum of antidepressant activity." | 2.39 | Moclobemide safety: monitoring a newly developed product in the 1990s. ( Hilton, S; Jaber, B; Ruch, R, 1995) |
| "Moclobemide has been shown to have similar efficacy to tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and nonselective, irreversible MAO inhibitors." | 2.39 | Moclobemide. An update of its pharmacological properties and therapeutic use. ( Benfield, P; Fulton, B, 1996) |
| "Moclobemide is a reversible and selective inhibitor of the enzyme monoamine oxidase (MAO) subtype A with a broad spectrum of antidepressant activity." | 2.38 | Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. ( Faulds, D; Fitton, A; Goa, KL, 1992) |
| "Depression is common in patients with senile dementia of the Alzheimer type (SDAT) and may precede the onset of the dementia; the underlying biological and neurotransmitter mechanisms may be common to both diseases, so far as norepinephrine lesions are concerned." | 2.38 | Depression and senile dementia of the Alzheimer type: a role for moclobemide. ( Chan-Palay, V, 1992) |
| "Imipramine was rather proinflammatory, whereas other tested drugs expressed immunosuppressive potential." | 1.43 | Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. ( Bryk, A; Bryniarski, P; Filipczak-Bryniarska, I; Kozlowski, M; Kuszmiersz, P; Myszka, M; Nazimek, K; Nowakowski, J; Strobel, S; Tyszka, A, 2016) |
| "Serotonin syndrome is caused by excess serotonin in the central nervous system." | 1.37 | [Serotonin syndrome in the course of drug-poisoning--case presentation]. ( Kostek, H; Kujawa, A; Majewska, M; Pyra, E; Szponar, J, 2011) |
| "Twenty-one inpatients with recurrent endogenous depression received MCB (150 mg t." | 1.35 | Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ( Miljkovic, B; Pokrajac, M; Rakic Ignjatovic, A; Timotijevic, I; Todorovic, D, 2009) |
| "Sertraline treatment did not modify the symptoms, which may suggest different mechanisms with regard to different antidepressant drug discontinuation syndromes." | 1.31 | Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. ( Berney, P; Curtin, F; Kaufmann, C, 2002) |
| " The dosage of moclobemide was usually started at 300 or 450 mg/day and increased to 600 mg/day only in some patients." | 1.30 | [Customary antidepressive treatment in Hungary: moclobemid therapy in everyday practice]. ( Bartkó, G, 1997) |
| " However, assessment of the results of previous studies is confounded by the relative lack of standards in diagnostic criteria, outcome measures, dosage and duration of treatment." | 1.29 | Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. ( Pétursson, H, 1995) |
| "The relationship between exposure to moclobemide and the occurrence of adverse events (AEs) was quantified by applying a population approach to data collected during phase III/IV studies." | 1.29 | Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. ( Banken, L; Guentert, TW; Hilton, S; Holford, NH, 1995) |
| " We discuss a possible relation between serotonin syndrome and a highly dosed combination therapy with moclobemide." | 1.29 | [Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis]. ( König, F; Löble, M; Wolfersdorf, M, 1996) |
| "1." | 1.29 | Moclobemide (Aurorix) in primary major depression. ( Barsi, J; Gábor, A; György, S; Rihmer, Z; Vad, G; Vég, K; Zalay, B, 1994) |
| "Tardive akathisia (TA) is a well-documented side-effect of neuroleptic treatment." | 1.28 | Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study. ( Demling, J; Ebert, D, 1991) |
| " A total of 2294 adverse events were reported by patients on moclobemide, mainly subjective symptoms (28." | 1.28 | Moclobemide (Ro 11-1163) safety in depressed patients. ( Hetzel, W; Moll, E, 1990) |
| "Amitriptyline was well tolerated when given to patients after or together with moclobemide." | 1.27 | Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. ( Eichler, HG; Fischbach, R; Gasic, S; Korn, A, 1986) |
| "Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A." | 1.27 | Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor. ( Davies, BM; Maguire, KP; Tiller, JW, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (12.96) | 18.7374 |
| 1990's | 172 (79.63) | 18.2507 |
| 2000's | 12 (5.56) | 29.6817 |
| 2010's | 4 (1.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldwin, DS | 1 |
| Green, M | 1 |
| Montgomery, SA | 1 |
| Nazimek, K | 1 |
| Kozlowski, M | 1 |
| Bryniarski, P | 1 |
| Strobel, S | 1 |
| Bryk, A | 1 |
| Myszka, M | 1 |
| Tyszka, A | 1 |
| Kuszmiersz, P | 1 |
| Nowakowski, J | 1 |
| Filipczak-Bryniarska, I | 1 |
| Rakic Ignjatovic, A | 1 |
| Miljkovic, B | 1 |
| Todorovic, D | 1 |
| Timotijevic, I | 1 |
| Pokrajac, M | 1 |
| Lang, FU | 1 |
| Hösch, H | 1 |
| Seibert, H | 1 |
| Klug, R | 1 |
| Köppler, D | 1 |
| Jäger, M | 1 |
| Majewska, M | 1 |
| Szponar, J | 1 |
| Pyra, E | 1 |
| Kostek, H | 1 |
| Kujawa, A | 1 |
| Müller, DJ | 1 |
| Schulze, TG | 1 |
| Macciardi, F | 1 |
| Ohlraun, S | 1 |
| Gross, MM | 1 |
| Scherk, H | 1 |
| Neidt, H | 1 |
| Syagailo, YV | 1 |
| Grässle, M | 1 |
| Nöthen, MM | 1 |
| Maier, W | 1 |
| Lesch, KP | 3 |
| Rietschel, M | 1 |
| Curtin, F | 1 |
| Berney, P | 1 |
| Kaufmann, C | 1 |
| Pini, S | 1 |
| Amador, XF | 1 |
| Dell'Osso, L | 1 |
| Baldini Rossi, N | 1 |
| Cassano, P | 1 |
| Savino, M | 1 |
| Cassano, GB | 1 |
| Bonnet, U | 1 |
| Labbate, LA | 1 |
| Croft, HA | 1 |
| Oleshansky, MA | 1 |
| Bonin-Guillaume, S | 1 |
| Blin, O | 1 |
| Degner, D | 1 |
| Kropp, S | 1 |
| Porzig, J | 1 |
| Grohmann, R | 1 |
| Rüther, E | 1 |
| Zivanović, O | 1 |
| Till, E | 1 |
| Casacchia, M | 3 |
| Carolei, A | 1 |
| Barba, C | 1 |
| Frontoni, M | 1 |
| Rossi, A | 2 |
| Meco, G | 1 |
| Zylberman, MR | 1 |
| Larsen, JK | 3 |
| Holm, P | 6 |
| Mikkelsen, PL | 1 |
| Mann, JJ | 1 |
| Aarons, SF | 1 |
| Frances, AJ | 1 |
| Brown, RD | 1 |
| Dajas, F | 2 |
| Lista, A | 1 |
| Barbeito, L | 1 |
| Gasic, S | 3 |
| Korn, A | 2 |
| Eichler, HG | 2 |
| Oberhummer, I | 1 |
| Zapotoczky, HG | 1 |
| Stefanis, CN | 3 |
| Alevizos, BH | 1 |
| Papadimitriou, GN | 1 |
| Markianos, M | 2 |
| Alevizos, B | 2 |
| Hatzimanolis, J | 2 |
| Stefanis, C | 1 |
| Kok, LP | 1 |
| Tsoi, WF | 1 |
| Lingjaerde, O | 1 |
| Jørgensen, J | 1 |
| Støren, R | 1 |
| Thomle, S | 1 |
| Wendt Raeder, L | 1 |
| Ruud, LE | 1 |
| Schetelig, E | 1 |
| Sveaas, HK | 1 |
| Leivestad, O | 1 |
| Priest, RG | 3 |
| Newburn, G | 2 |
| Edwards, R | 2 |
| Thomas, H | 2 |
| Collier, J | 2 |
| Fox, K | 2 |
| Collins, C | 2 |
| Cramer, D | 1 |
| Reeves, J | 1 |
| Caracatsanis, A | 1 |
| Angst, J | 6 |
| Amrein, R | 9 |
| Stabl, M | 15 |
| Kragh-Sørensen, P | 3 |
| Müller, B | 1 |
| Andersen, JV | 1 |
| Buch, D | 1 |
| Stage, KB | 3 |
| Tiller, JW | 4 |
| Johnson, GF | 1 |
| Burrows, GD | 4 |
| Gagiano, CA | 3 |
| Müller, FG | 2 |
| Berk, M | 1 |
| Joubert, PM | 1 |
| Brown, RG | 1 |
| Schall, R | 3 |
| Gattaz, WF | 1 |
| Vogel, P | 1 |
| Kick, H | 1 |
| Kohnen, R | 5 |
| de Kock, RF | 1 |
| Kasas, A | 2 |
| Blajev, B | 2 |
| Bajetta, G | 1 |
| Zöchling, R | 1 |
| Holsboer-Trachsler, E | 1 |
| Realini, R | 1 |
| Schäublin-Loidl, M | 1 |
| Walker, V | 1 |
| Streiner, DL | 1 |
| Novosel, S | 2 |
| Rocchi, A | 1 |
| Levine, MA | 1 |
| Dean, DM | 1 |
| Hilton, S | 2 |
| Jaber, B | 1 |
| Ruch, R | 1 |
| Guentert, TW | 1 |
| Banken, L | 1 |
| Holford, NH | 1 |
| Reynaert, C | 1 |
| Parent, M | 1 |
| Mirel, J | 1 |
| Janne, P | 1 |
| Haazen, L | 2 |
| Lonnqvist, J | 3 |
| Sihvo, S | 3 |
| Syvälahti, E | 3 |
| Sintonen, H | 2 |
| Kiviruusu, O | 2 |
| Pitkanen, H | 1 |
| Gleiter, C | 1 |
| Volz, HP | 3 |
| Lauerma, H | 1 |
| Indran, SK | 1 |
| Dingemanse, J | 1 |
| Kneer, J | 1 |
| Fotteler, B | 1 |
| Groen, H | 1 |
| Peeters, PA | 1 |
| Jonkman, JH | 1 |
| Nair, NP | 5 |
| Amin, M | 2 |
| Katona, C | 2 |
| Klitgaard, N | 2 |
| Ng Ying Kin, NM | 1 |
| Kühn, H | 1 |
| Leek, CA | 1 |
| Hartmann, D | 1 |
| Cesura, AM | 1 |
| Schmid-Burgk, W | 7 |
| Paykel, ES | 1 |
| Pétursson, H | 2 |
| Ahmed, SK | 3 |
| Kin, NM | 3 |
| West, TE | 2 |
| Youdim, MB | 1 |
| Gex-Fabry, M | 1 |
| Balant-Gorgia, AE | 1 |
| Balant, LP | 1 |
| Norman, TR | 3 |
| Fahy, TJ | 1 |
| Menkes, DB | 3 |
| Wood, K | 1 |
| Wooods, D | 1 |
| Gram, LF | 1 |
| Isacsson, G | 1 |
| Bergman, U | 1 |
| Lapierre, YD | 3 |
| Hickie, I | 1 |
| Wilson, A | 1 |
| Campos, JA | 1 |
| Deitos, TF | 1 |
| Lima, MC | 1 |
| Salomão, K | 1 |
| Salomão, S | 1 |
| Souza, AC | 1 |
| Hart, GA | 1 |
| Bodemer, W | 1 |
| Gachoud, JP | 4 |
| Dick, P | 1 |
| Köhler, M | 2 |
| Geerts, S | 1 |
| Bruynooghe, F | 1 |
| De Cuyper, H | 1 |
| Demeulemeester, F | 1 |
| Vaz-Serra, A | 1 |
| Figueira, ML | 1 |
| Firmino, H | 1 |
| Albuquerque, AJ | 1 |
| Jara, JM | 1 |
| Pestana, LC | 1 |
| Pancheri, P | 1 |
| Delle Chiaie, R | 1 |
| Donnini, M | 1 |
| Seripa, S | 1 |
| Gambino, C | 1 |
| Vicario, E | 1 |
| Trillo, L | 1 |
| Moll, E | 6 |
| Neumann, N | 2 |
| McFarlane, HJ | 1 |
| Appelberg, B | 1 |
| Koskinen, T | 2 |
| Mannikko, T | 1 |
| Mehtonen, OP | 1 |
| Naarala, M | 1 |
| Auvinen, J | 2 |
| Aymard, N | 1 |
| Honore, P | 1 |
| Carbuccia, I | 1 |
| Heinze, G | 2 |
| Rossel, L | 3 |
| Gabelic, I | 3 |
| Galeano-Munoz, J | 1 |
| Allen, SR | 2 |
| Steinmeyer, EM | 1 |
| Vorbach, EU | 1 |
| Arnoldt, KH | 1 |
| Rütten, J | 1 |
| Rihmer, Z | 1 |
| Barsi, J | 1 |
| Vad, G | 1 |
| György, S | 1 |
| Zalay, B | 1 |
| Vég, K | 1 |
| Gábor, A | 1 |
| Bech, P | 2 |
| Hale, AS | 1 |
| Joffe, RT | 1 |
| Bakish, D | 3 |
| Kusalic, M | 1 |
| Engelsmann, F | 1 |
| Bradwejn, J | 2 |
| Scheidegger, P | 1 |
| Spoov, J | 1 |
| Suominen, JY | 1 |
| Lahdelma, RL | 1 |
| Katila, H | 1 |
| Kymäläinen, O | 1 |
| Isometsä, E | 1 |
| Liukko, H | 1 |
| Silverstone, T | 1 |
| Hetzel, W | 3 |
| Woggon, B | 1 |
| Philipp, M | 3 |
| Benkert, O | 1 |
| Williams, R | 1 |
| Edwards, RA | 1 |
| Newburn, GM | 2 |
| Mullen, R | 1 |
| Segkar, C | 1 |
| Rimón, R | 1 |
| Jääskeläinen, J | 1 |
| Kaartinen, P | 1 |
| Kalli, A | 1 |
| Kilponen, E | 1 |
| Nikkilä, H | 1 |
| Pirttiperä, V | 1 |
| Seppälä, J | 1 |
| Beaumont, G | 1 |
| Gringras, M | 1 |
| Hobbs, FD | 1 |
| Drury, VW | 1 |
| Freeling, P | 1 |
| Tylee, A | 1 |
| Shanley, DF | 1 |
| Comber, H | 1 |
| Little, S | 1 |
| Hill, S | 1 |
| Minot, R | 1 |
| Luthringer, R | 1 |
| Macher, JP | 2 |
| Paykel, E | 1 |
| Goldberg, D | 1 |
| Stanton, J | 1 |
| Møller, SE | 1 |
| Delini-Stula, A | 3 |
| Mikkelsen, H | 4 |
| Illi, A | 1 |
| Sundberg, S | 1 |
| Ojala-Karlsson, P | 1 |
| Scheinin, M | 1 |
| Gordin, A | 1 |
| Coupland, NJ | 1 |
| Wilson, SJ | 1 |
| Potokar, JP | 1 |
| Bell, CE | 1 |
| Bailey, JE | 1 |
| Nutt, DJ | 1 |
| Fischer, P | 1 |
| Radat, F | 2 |
| Berlin, I | 2 |
| Varoquaux, O | 1 |
| Ferreri, M | 2 |
| Puech, A | 1 |
| Galderisi, S | 1 |
| Mucci, A | 1 |
| Bucci, P | 1 |
| Mignone, ML | 1 |
| Maj, M | 1 |
| Roth, M | 2 |
| Mountjoy, CQ | 1 |
| Lecrubier, Y | 2 |
| Pedarriosse, AM | 2 |
| Payan, C | 3 |
| Fulton, B | 1 |
| Benfield, P | 1 |
| Hawley, CJ | 1 |
| Quick, SJ | 1 |
| Ratnam, S | 1 |
| Pattinson, HA | 1 |
| McPhee, S | 1 |
| Spreux-Varoquaux, O | 1 |
| Elatki, S | 1 |
| Puech, AJ | 1 |
| Myronuk, LD | 1 |
| Weiss, M | 1 |
| Cotter, L | 1 |
| Gleiter, CH | 1 |
| Möller, HJ | 1 |
| König, F | 3 |
| Löble, M | 2 |
| Wolfersdorf, M | 3 |
| Laux, G | 10 |
| Baier, D | 4 |
| Linden, M | 1 |
| Gothe, H | 1 |
| Landmann, R | 1 |
| Schaub, B | 1 |
| Link, S | 1 |
| Wacker, HR | 1 |
| Joffe, R | 1 |
| McKenna, K | 1 |
| Bland, R | 1 |
| Kennedy, S | 1 |
| Ingram, P | 1 |
| Reesal, R | 1 |
| Rickhi, BG | 1 |
| Beauclair, L | 1 |
| Chouinard, G | 1 |
| Annable, L | 1 |
| Gjerris, A | 2 |
| White, PD | 1 |
| Cleary, KJ | 1 |
| Iakovlev, VA | 1 |
| Ramaekers, JG | 1 |
| Ansseau, M | 1 |
| Muntjewerff, ND | 1 |
| Sweens, JP | 1 |
| O'Hanlon, JF | 1 |
| Wössner, S | 1 |
| Hauger, B | 1 |
| Bartkó, G | 1 |
| Steur, EN | 1 |
| Ballering, LA | 1 |
| Schwartz, G | 1 |
| Kragh-Sorensen, P | 1 |
| Song, WY | 1 |
| Stage, K | 1 |
| Püchler, K | 1 |
| Plenker, A | 1 |
| Gillman, PK | 1 |
| Jouvent, R | 2 |
| Le Houezec, J | 1 |
| Fermanian, J | 2 |
| Millet, V | 1 |
| Dufour, H | 1 |
| Lestra, C | 1 |
| d'Amato, T | 1 |
| Ghaemmaghami, C | 1 |
| Perret-Liaudet, A | 1 |
| Broyer, M | 1 |
| Renaud, B | 1 |
| Dalery, J | 1 |
| Chamba, G | 1 |
| Ramasubbu, R | 1 |
| O'Brien, BJ | 1 |
| Torrance, G | 1 |
| Streiner, D | 1 |
| Stassen, HH | 1 |
| Scholz, HJ | 1 |
| Versiani, M | 5 |
| Barak, Y | 1 |
| Ur, E | 1 |
| Achiron, A | 1 |
| Birkenhäger, TK | 2 |
| Moleman, P | 2 |
| Søgaard, J | 1 |
| Lane, R | 1 |
| Latimer, P | 1 |
| Behnke, K | 1 |
| Christiansen, PE | 1 |
| Nielsen, B | 1 |
| Ravindran, AV | 1 |
| Reesal, RT | 1 |
| Goodwin, DP | 1 |
| Mackay, FR | 1 |
| Dunn, NR | 1 |
| Martin, RM | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Kennedy, SH | 2 |
| Eisfeld, BS | 1 |
| Dickens, SE | 1 |
| Bacchiochi, JR | 1 |
| Bagby, RM | 1 |
| Magder, DM | 1 |
| Aleksic, I | 1 |
| Hickie, IB | 1 |
| Wilson, AJ | 1 |
| Wright, JM | 1 |
| Bennett, BK | 1 |
| Wakefield, D | 1 |
| Lloyd, AR | 1 |
| Botte, L | 2 |
| Evrard, JL | 2 |
| Gilles, C | 2 |
| Stenier, P | 1 |
| Wolfrum, C | 4 |
| Fitton, A | 1 |
| Faulds, D | 1 |
| Goa, KL | 1 |
| Guelfi, JD | 3 |
| Wiens, A | 1 |
| Ellis, J | 1 |
| Alda, M | 1 |
| Lapierre, Y | 1 |
| Evans, L | 1 |
| George, T | 1 |
| O'Sullivan, B | 1 |
| Mitchell, P | 1 |
| Johnson, G | 1 |
| Adena, M | 1 |
| Chaudhry, HR | 1 |
| Nolen, WA | 1 |
| Bieck, PR | 1 |
| Antonin, KH | 1 |
| Schmidt, E | 1 |
| Chen, DT | 1 |
| Bougerol, T | 1 |
| Uchida, C | 1 |
| Ose, E | 2 |
| Lemoine, P | 1 |
| Mirabaud, C | 2 |
| Wegscheider, R | 1 |
| Chan-Palay, V | 1 |
| Ferner, U | 1 |
| Ammar, S | 1 |
| Widlöcher, D | 1 |
| Nair, N | 1 |
| McClure, J | 1 |
| Remick, R | 1 |
| Bulger, L | 1 |
| Manfredi, R | 1 |
| Judd, FK | 1 |
| Ebert, D | 1 |
| Demling, J | 1 |
| Anderson, J | 1 |
| Bille, A | 1 |
| Christensen, EM | 1 |
| Høyer, E | 1 |
| Jensen, H | 1 |
| Mejlhede, A | 1 |
| Langagergaard, A | 1 |
| Barrelet, L | 1 |
| Bolzani, L | 1 |
| de Saussure, C | 1 |
| Van, H | 1 |
| Mueller, T | 1 |
| Fraser, AR | 1 |
| Mullen, PE | 1 |
| Hebenstreit, GF | 1 |
| Loidl, M | 1 |
| Baumhackl, U | 2 |
| Gallhofer, B | 1 |
| Geretsegger, C | 2 |
| Radmayr, E | 2 |
| Saletu, M | 1 |
| Schöny, W | 1 |
| Classen, W | 4 |
| Sofic, E | 2 |
| Becker, T | 3 |
| Riederer, P | 2 |
| Struck, M | 2 |
| Beckmann, H | 3 |
| Nardi, AE | 3 |
| Figueira, IL | 1 |
| Ucha Udabe, R | 1 |
| Márquez, CA | 2 |
| Traballi, CA | 1 |
| Portes, N | 1 |
| Merz-Frei, K | 1 |
| Monti, JM | 2 |
| Alterwain, P | 2 |
| Monti, D | 1 |
| Liebowitz, MR | 1 |
| Hollander, E | 1 |
| Schneier, F | 1 |
| Campeas, R | 1 |
| Welkowitz, L | 1 |
| Hatterer, J | 1 |
| Fallon, B | 1 |
| Mesters, P | 1 |
| Berger, M | 4 |
| Hellstern, K | 5 |
| Ward, J | 2 |
| Funke, HJ | 1 |
| Moritz, E | 1 |
| Malanowski, H | 2 |
| Civeira, J | 1 |
| Cervera, S | 1 |
| Giner, J | 1 |
| Wirz, R | 1 |
| Klar, K | 1 |
| Dierick, M | 1 |
| Cattiez, P | 1 |
| Franck, G | 1 |
| Burton, P | 1 |
| Defleur, J | 1 |
| Hermans, W | 1 |
| Roelandts, A | 1 |
| Beckers, G | 1 |
| Vereecken, A | 1 |
| de Bleeker, E | 1 |
| Jaunes, C | 1 |
| Sieben, G | 1 |
| Faidherbe, J | 1 |
| Mundim, FD | 2 |
| Alves, A | 1 |
| Bizière, K | 3 |
| Kuhn, B | 1 |
| De Vanna, M | 1 |
| Kummer, J | 1 |
| Agnoli, A | 1 |
| Gentili, P | 1 |
| Lorizio, A | 1 |
| Anand, R | 1 |
| Zimmer, R | 2 |
| Fischbach, R | 4 |
| Breuel, HP | 1 |
| Gieschke, R | 1 |
| Fritze, J | 1 |
| Koronakis, P | 1 |
| Schoerlin, MP | 1 |
| Carl, G | 1 |
| Schweitzer, I | 2 |
| Tiller, J | 1 |
| Maguire, K | 1 |
| Davies, B | 1 |
| Koczkas, C | 1 |
| Karlsson, A | 1 |
| Nagy, A | 1 |
| Ulverås, L | 1 |
| Wenedikter, O | 1 |
| Maguire, KP | 2 |
| Davis, B | 1 |
| Hebenstreit, G | 1 |
| Oggero, U | 1 |
| Capponi, R | 1 |
| Heinze-Martin, G | 1 |
| Poleo, MA | 1 |
| Rivero-Almanzor, LE | 1 |
| Burgess, CD | 1 |
| Mellsop, GW | 1 |
| Alves, AB | 1 |
| Vine, R | 1 |
| Dowson, JH | 1 |
| Lensch, K | 1 |
| Fuchs, G | 1 |
| Böning, J | 1 |
| Milech, U | 1 |
| Davies, BM | 1 |
| Sanchez, A | 1 |
36 reviews available for moclobemide and Depression, Endogenous
| Article | Year |
|---|---|
Moclobemide: therapeutic use and clinical studies.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Interactions | 2003 |
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin; | 2003 |
Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. Chairman's introduction.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1995 |
Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Humans; Mo | 1995 |
Moclobemide safety: monitoring a newly developed product in the 1990s.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Humans; Male; Middle Ag | 1995 |
Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients.
Topics: Aged; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Dose-Response Relationship, | 1995 |
The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
Topics: Benzamides; Cheese; Clorgyline; Depressive Disorder; Humans; Hypertension; Moclobemide; Monoamine Ox | 1995 |
A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Drug Interactions; Drug Syne | 1995 |
Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Topics: Benzamides; Brain; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Isoenzymes; Metabo | 1993 |
Pharmacological therapy of dysthymia.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzamides; Benzodiazepines; Depressive Disorde | 1994 |
Acute therapy of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Drug Admin | 1993 |
New antidepressants: use in high-risk patients.
Topics: Age Factors; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Drug Interactions; Epilep | 1993 |
Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Diagnosis-Related Groups; Humans; Imipramine | 1993 |
Moclobemide--placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Cro | 1993 |
RIMA--a new concept in the treatment of depression with moclobemide.
Topics: Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Humans; Long-T | 1993 |
The role of moclobemide in endogenous depression: a survey of recent data.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Humans; Meta-Analysis as Topic; M | 1993 |
Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzamides; Clinical Trials as | 1995 |
Moclobemide. An update of its pharmacological properties and therapeutic use.
Topics: Age Factors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical | 1996 |
Moclobemide: a paradigm of research in clinical psychopharmacology.
Topics: Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Humans; Moclobemid | 1996 |
[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase; Mono | 1996 |
Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Comor | 1998 |
[Two new antidepressants: mirtazapine and venlafaxine].
Topics: Adrenergic alpha-Antagonists; Benzamides; Cyclohexanols; Depressive Disorder; Drug Interactions; Fem | 1999 |
Efficacy of moclobemide in different patient groups: a meta-analysis of studies.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Benzamides; Benzodiazepines; Depressive Dis | 1992 |
Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
Topics: Animals; Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide | 1992 |
RIMA: a safe concept in the treatment of depression with moclobemide.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Depressive Disorder; Drug In | 1992 |
[Moclobemide (Aurorix), the first MAO-A-inhibitor: really something new?].
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1992 |
Depression and senile dementia of the Alzheimer type: a role for moclobemide.
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide | 1992 |
Moclobemide: a range of opportunities.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Mental Disorders; Moclobemide | 1992 |
Active control equivalence trials: some methodological aspects.
Topics: Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Humans; Moclobemid | 1992 |
Theoretical considerations and perspectives on the onset of action of moclobemide.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide | 1992 |
New pharmacological approaches to the management of depression: from theory to clinical practice.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Fluoxetine; Humans; Moclobemide; Pyridazines | 1992 |
Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
Topics: Antidepressive Agents; Benzamides; Borderline Personality Disorder; Bulimia; Combined Modality Thera | 1990 |
Interaction studies with moclobemide.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Drug Interactions; Drug Therapy, Combination | 1990 |
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Depressive Disorder; Humans; | 1989 |
[Moclobemide in the treatment of depression--an overview].
Topics: Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Double-Blind Metho | 1989 |
MAO inhibitors in mental disease: their current status.
Topics: Benzamides; Clorgyline; Depressive Disorder; Drug Therapy, Combination; Humans; Moclobemide; Monoami | 1987 |
126 trials available for moclobemide and Depression, Endogenous
| Article | Year |
|---|---|
Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study.
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Humans; | 2014 |
Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Comorbidity; D | 2003 |
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
Topics: Adult; Antidepressive Agents; Benzamides; Bipolar Disorder; Clinical Trials as Topic; Depressive Dis | 1984 |
Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial.
Topics: Adult; Aged; Benzamides; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Dizziness; Dou | 1984 |
Studies of selective and reversible monoamine oxidase inhibitors.
Topics: Animals; Benzamides; Blood Platelets; Brain; Clinical Trials as Topic; Depressive Disorder; Dopamine | 1984 |
Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
Topics: Adult; Benzamides; Blood Pressure; Coronary Circulation; Depressive Disorder; Female; Heart Rate; Hu | 1983 |
Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
Topics: Adult; Benzamides; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Female; Humans; | 1982 |
A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Hu | 1995 |
A double-blind comparison of moclobemide and doxepin in depressed general practice patients.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Dose-Respo | 1995 |
A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R)
Topics: Adult; Antidepressive Agents; Anxiety; Benzamides; Depressive Disorder; Double-Blind Method; Female; | 1995 |
Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clomipramine; Depr | 1995 |
Moclobemide for depression: an Australian psychiatric practice study.
Topics: Adult; Antidepressive Agents; Australia; Benzamides; Depressive Disorder; Double-Blind Method; Femal | 1995 |
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; | 1995 |
Moclobemide versus fluoxetine in the treatment of inpatients with major depression.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blin | 1995 |
Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Follow-U | 1995 |
A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzamides; Depressive Disorde | 1995 |
Health-related quality of life in patients with major depression who are treated with moclobemide.
Topics: Adolescent; Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Health; Humans; M | 1995 |
Moclobemide versus fluoxetine for a major depressive episode.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relat | 1995 |
Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.
Topics: Acute Disease; Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relation | 1995 |
[Moclobemide].
Topics: Antidepressive Agents; Benzamides; Depression; Depressive Disorder; Humans; Isoenzymes; Moclobemide; | 1995 |
Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dizziness; Female; Follow-Up Studies; | 1995 |
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive D | 1995 |
Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.
Topics: Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Doub | 1995 |
Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide.
Topics: Adult; Aged; Aged, 80 and over; Aging; Benzamides; Chromatography, Gas; Depressive Disorder; Drug In | 1995 |
Moclobemide and fluoxetine in atypical depression: a double-blind trial.
Topics: Adult; Anticonvulsants; Benzamides; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Hu | 1994 |
Use of sleep questionnaires in assessing the effect of moclobemide on the sleep profiles of depressive patients.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Humans; Male; Moclobemide; Ps | 1994 |
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.
Topics: Adult; Antidepressive Agents; Benzamides; Body Weight; Depressive Disorder; Double-Blind Method; Dru | 1994 |
Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Family Practice; Female | 1994 |
Moclobemide versus fluoxetine for major depressive episodes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Doub | 1994 |
Multicenter double-blind study of moclobemide and maprotiline.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; | 1994 |
Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.
Topics: Aged; Antidepressive Agents; Anxiety; Benzamides; Cognition; Depressive Disorder; Double-Blind Metho | 1994 |
Safety and efficacy during long-term treatment with moclobemide.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Blood Pressure; Body Weight; Depr | 1994 |
A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. UK Moclobemide Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method | 1994 |
Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.
Topics: Adult; Benzamides; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl | 1994 |
Double-blind comparison of moclobemide and tranylcypromine in depression.
Topics: Adult; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Mocl | 1993 |
Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups.
Topics: Adolescent; Adult; Aged; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; | 1993 |
Combined SSRI-moclobemide treatment of psychiatric illness.
Topics: 1-Naphthylamine; Adult; Benzamides; Depressive Disorder; Drug Administration Schedule; Drug Therapy, | 1994 |
Thyroid functioning during treatment for depression.
Topics: Adult; Amitriptyline; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Mi | 1993 |
Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
Topics: Adult; Aged; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Method; Female; Half-Life; | 1993 |
Do reversed depressive symptoms occur together as a syndrome?
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Appetite; Benzamides; Depressive Disorder; Female; | 1993 |
A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction.
Topics: Adult; Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Doxep | 1993 |
A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Blood Pressure; Depressive Disorder; Dose-Response Relat | 1993 |
Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
Topics: Adult; Aged; Ambulatory Care; Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Dou | 1993 |
A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice.
Topics: Adolescent; Adult; Aged; Benzamides; Depressive Disorder; Dothiepin; Double-Blind Method; England; F | 1993 |
Effect of moclobemide on the psychophysiology of sleep/wake cycles: a neuroelectrophysiological study of depressed patients administered with moclobemide.
Topics: Adult; Benzamides; Brain Mapping; Depressive Disorder; Dose-Response Relationship, Drug; Electroence | 1993 |
The Australian multicentre moclobemide trial.
Topics: Amitriptyline; Australia; Benzamides; Bias; Depressive Disorder; Humans; Moclobemide; Monoamine Oxid | 1993 |
Plasma amino acid profiles in relation to clinical response to moclobemide in patients with major depression. Danish University Antidepressant Group.
Topics: Adult; Aged; Amino Acids; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Method; Female | 1993 |
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Topics: Administration, Oral; Adult; Analysis of Variance; Antidepressive Agents; Antiparkinson Agents; Benz | 1996 |
A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes.
Topics: Adolescent; Adult; Aged; Benzamides; Blood Pressure; Depressive Disorder; Female; Heart Rate; Humans | 1995 |
[Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?].
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Double-Bli | 1996 |
Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Cognition Disorders; Comorbidity; Dement | 1996 |
Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group.
Topics: Adolescent; Adult; Aged; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Method; Female; | 1995 |
Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Topics: Adult; Benzamides; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Headache; Hum | 1996 |
Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antidepressive Agents; Benzamides; Biomarkers; Depressive Dis | 1996 |
Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Benzamides; Depressive Disorder; Drug Interaction | 1997 |
What happens to patients after the end of a clinical trial? Systematic follow-up observational study of an open moclobemide trial in major depression.
Topics: Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Drug Monitoring; F | 1997 |
Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Central Nervous System Agents; Cytokines | 1997 |
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Depressive Disor | 1997 |
The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group.
Topics: Antidepressive Agents; Benzamides; Clomipramine; Depressive Disorder; Drug Therapy, Combination; Hum | 1997 |
An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome.
Topics: Adult; Benzamides; Depressive Disorder; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged | 1997 |
Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
Topics: Analysis of Variance; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Drug Resist | 1997 |
[Special aspects of antidepressive therapy].
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1994 |
Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Automobile Driving; Benzamides; | 1997 |
Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Drug Interactions; Drug Resista | 1997 |
Moclobemide and selegeline in the treatment of depression in Parkinson's disease.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1997 |
The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Dexa | 1997 |
Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; M | 1997 |
Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
Topics: Adult; Affective Symptoms; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricy | 1998 |
Assessing the economic value of a new antidepressant. A willingness-to-pay approach.
Topics: Adult; Antidepressive Agents; Benzamides; Cost-Benefit Analysis; Depressive Disorder; Female; Humans | 1995 |
Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Gen | 1999 |
Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies.
Topics: Adult; Aged; Benzamides; Blood Pressure; Cardiovascular Diseases; Comorbidity; Depression; Depressiv | 1999 |
Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial.
Topics: Adult; Depressive Disorder; Female; Humans; Male; Middle Aged; Moclobemide; Multiple Sclerosis; Pilo | 1999 |
A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.
Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum | 1999 |
Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Lithium; Male; Moclobe | 2000 |
Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury.
Topics: Adolescent; Adult; Brain Injuries; Child; Depressive Disorder; Female; Humans; Male; Middle Aged; Mo | 1999 |
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fl | 2000 |
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.
Topics: Adult; Comorbidity; Depressive Disorder; Double-Blind Method; Fatigue Syndrome, Chronic; Female; Hum | 2000 |
Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
Topics: Adult; Benzamides; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 1992 |
The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Clomipramine; Depressive Disorder; Humans; Imipramine; | 1992 |
A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression.
Topics: Adult; Amitriptyline; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Mi | 1992 |
An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression.
Topics: Adult; Aged; Amitriptyline; Anxiety Disorders; Benzamides; Depressive Disorder; Double-Blind Method; | 1992 |
Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Fluvoxam | 1992 |
Moclobemide and placebo in mild major depression: a double-blind randomized trial.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Hu | 1992 |
A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Humans; Moclobem | 1992 |
A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Dibenzocyc | 1992 |
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.
Topics: Adult; Amitriptyline; Antidepressive Agents; Benzamides; Body Weight; Canada; Depressive Disorder; F | 1992 |
Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Meth | 1992 |
Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Meth | 1991 |
[Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes].
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Fluvoxamine; Humans; Ma | 1991 |
A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders.
Topics: Adult; Amitriptyline; Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Double | 1990 |
Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Austria; Benzamides; Depressive Disorder; Double-Blind M | 1990 |
Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.
Topics: Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Maprotiline; Middle Aged | 1990 |
Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
Topics: Benzamides; Catecholamines; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle A | 1990 |
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Blood Pressure; Depressi | 1990 |
Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzamides; Bipolar Disorder; Depressive Disorder; D | 1990 |
Moclobemide (Ro 11-1163) in long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind | 1990 |
The effects of moclobemide on nocturnal sleep of depressed patients.
Topics: Adult; Arousal; Benzamides; Depressive Disorder; Electroencephalography; Female; Humans; Male; Middl | 1990 |
Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Dos | 1990 |
Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants.
Topics: Animals; Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Isoenzymes; Moclobemide; Mo | 1990 |
Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.
Topics: Antidepressive Agents; Belgium; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxid | 1990 |
Moclobemide (Ro 11-1163) versus imipramine in the treatment of depression.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Imipramine; Moclobemide; Monoamine O | 1990 |
Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Desipramine; Dose-Response R | 1990 |
Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.
Topics: Antidepressive Agents; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Method; Germany; | 1990 |
Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain.
Topics: Adult; Antidepressive Agents; Benzamides; Clomipramine; Depressive Disorder; Dose-Response Relations | 1990 |
Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium.
Topics: Antidepressive Agents; Belgium; Benzamides; Clomipramine; Depressive Disorder; Double-Blind Method; | 1990 |
Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Belgium; Benzamides; Depressive Disorder; Double- | 1990 |
Moclobemide, imipramine and placebo in the treatment of major depression.
Topics: Ambulatory Care; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Humans | 1990 |
Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Imipram | 1990 |
Moclobemide versus tranylcypromine in the treatment of depression.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Humans; Moclobemide; Monoami | 1990 |
Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Feeding Behavior; Heart Rate | 1990 |
Moclobemide compared with second-generation antidepressants in elderly people.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method | 1990 |
Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Dose-Response Relationship, | 1990 |
Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.
Topics: Adult; Benzamides; Biogenic Monoamines; Depressive Disorder; Double-Blind Method; Female; Homovanill | 1989 |
[Moclobemide in the long-term treatment of depressed patients].
Topics: Adult; Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Female; Fol | 1989 |
Treatment of atypical depression with moclobemide: a sequential double controlled study.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Diaze | 1989 |
A comparison of moclobemide and imipramine in treatment of depression.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Dose- | 1989 |
Moclobemide and clomipramine in endogenous depression. A randomized clinical trial.
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Clinical Trials as Topic; Clomipramine; Depressive D | 1989 |
Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
Topics: Anthracenes; Benzamides; Blood Pressure; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1989 |
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Depressive Disorder; Humans; | 1989 |
[Moclobemide in the treatment of depression--an overview].
Topics: Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depressive Disorder; Double-Blind Metho | 1989 |
[Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic | 1989 |
Is diazepam an antidepressant?
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Arousal; Benzamides; Depressive Disorder; Diazepam; | 1989 |
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
Topics: Adjustment Disorders; Adult; Aged; Aged, 80 and over; Austria; Benzamides; Bipolar Disorder; Depress | 1989 |
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Benzamides; Bipolar Disorder; Depressive Disorder; Do | 1989 |
Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
Topics: Adult; Benzamides; Depressive Disorder; Female; Humans; Imipramine; Male; Middle Aged; Moclobemide; | 1989 |
A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
Topics: Adult; Aged; Benzamides; Bipolar Disorder; Blood Platelets; Blood Pressure; Clinical Trials as Topic | 1987 |
56 other studies available for moclobemide and Depression, Endogenous
| Article | Year |
|---|---|
Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages.
Topics: Animals; Antidepressive Agents; Biomarkers; Cytokines; Depressive Disorder; Dermatitis, Contact; Flu | 2016 |
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Carbamazepine; Case-Control Studie | 2009 |
[Obstructive sleep apnoea syndrome as the cause of atypical depression].
Topics: Adult; Antidepressive Agents; Body Weight; Continuous Positive Airway Pressure; Depressive Disorder; | 2011 |
[Serotonin syndrome in the course of drug-poisoning--case presentation].
Topics: Alcoholic Intoxication; Alkaloids; Azocines; Bradycardia; Cyclohexanols; Depressive Disorder; Electr | 2011 |
Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter.
Topics: Adult; Aged; Alleles; Antidepressive Agents; Depressive Disorder; Female; Humans; Male; Middle Aged; | 2002 |
Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms.
Topics: Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; | 2002 |
[Biological treatment of depression in the elderly].
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Brain; Depressive Disorder; Dose-Response Relationsh | 2004 |
Pseudohallucinations associated with moclobemide: a case report.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Hallucinations; Humans; Male; Mianserin; Mirtazap | 2005 |
[Serotonin syndrome--a case account].
Topics: Antidepressive Agents; Depressive Disorder; Humans; Male; Middle Aged; Moclobemide; Monoamine Oxidas | 1992 |
High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163).
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Humans; Male; Middle Ag | 1984 |
Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Topics: Adult; Arousal; Benzamides; Biogenic Amines; Bipolar Disorder; Chromatography, High Pressure Liquid; | 1994 |
Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Huma | 1995 |
Moclobemide for depression.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1994 |
A case of moclobemide-induced hyperorgasmia.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Female; Follow-Up Studies; Humans; Li | 1995 |
Relevance of reversible inhibitors of monoamine oxidase type A and of reuptake inhibition for noradrenaline turnover.
Topics: Animals; Benzamides; Brain; Cytoplasm; Depressive Disorder; Desipramine; Humans; Kinetics; Moclobemi | 1995 |
Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Ox | 1995 |
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.
Topics: Benzamides; Depressive Disorder; Fluoxetine; Humans; Imipramine; Moclobemide; Monoamine Oxidase Inhi | 1995 |
Efficacy and adverse effects of moclobemide.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1994 |
Efficacy and adverse effects of moclobemide.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1994 |
Moclobemide.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhib | 1994 |
A catecholamine model of fatigue.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Benzamides; Brain; Catecholamines; Depressive D | 1994 |
Anaesthesia and the new generation monoamine oxidase inhibitors.
Topics: Adult; Anesthesia, General; Anesthetics; Benzamides; Depressive Disorder; Drug Interactions; Female; | 1994 |
Determination of 5-hydroxytryptamine and tryptophan by liquid chromatography in whole blood. Its interest for the exploration of mental disorders.
Topics: Adult; Antidepressive Agents, Tricyclic; Benzamides; Chromatography, High Pressure Liquid; Clomipram | 1994 |
[Moclobemide in treatment of somatoform depression. A case report].
Topics: Activities of Daily Living; Aged; Benzamides; Depressive Disorder; Female; Humans; Moclobemide; Mono | 1994 |
Moclobemide (Aurorix) in primary major depression.
Topics: Adult; Aged; Benzamides; Biomarkers; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; H | 1994 |
RIMAs in subtypes of depression: focus on moclobemide. Third International Symposium, Vienna, 29-31 March 1992.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1993 |
Depression in medical illness. Workshop report.
Topics: Aged; Antidepressive Agents; Benzamides; Depressive Disorder; Family Practice; Humans; Moclobemide; | 1993 |
Syndromal subgroups of depression. Workshop report.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Recurrence | 1993 |
Clinical, endocrine and neurochemical effects of moclobemide in depressed patients.
Topics: Adult; Benzamides; Blood Platelets; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortiso | 1993 |
Serotonin syndrome in the elderly after antidepressive monotherapy.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Benzamid | 1995 |
Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices.
Topics: Adult; Antidepressive Agents; Arousal; Attention; Benzamides; Cognition Disorders; Depressive Disord | 1996 |
Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Benzamides; Comorbidity; Depressive Disorder; | 1996 |
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzamides; Depressive Disorder; Diagnosis, | 1996 |
[The comparative efficacy of Aurorix and amitriptyline in treating depressions].
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Dep | 1997 |
[Customary antidepressive treatment in Hungary: moclobemid therapy in everyday practice].
Topics: Antidepressive Agents; Benzamides; Data Collection; Depressive Disorder; Dose-Response Relationship, | 1997 |
Serotonin syndrome--clomipramine too soon after moclobemide?
Topics: Adult; Benzamides; Central Nervous System Diseases; Clomipramine; Depressive Disorder; Drug Interact | 1997 |
Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Benzamides; Biomarkers; Biopterins | 1998 |
Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Depressive Disor | 1999 |
[Various forms of risk factors of antidepressive agents for influencing sexual functions. Moclobemid is first choice for the therapy of sexually active patients with depression].
Topics: Antidepressive Agents; Anxiety; Benzamides; Depression; Depressive Disorder; Female; Humans; Male; M | 1999 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Pract | 1999 |
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Cyclohexanols; Depressive Disorder; Female; Humans; Libido; Male; Middle Aged; Moclobemide; M | 2000 |
New perspectives on the treatment of depression.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1992 |
Clinical use of moclobemide in Kleine-Levin syndrome.
Topics: Benzamides; Depressive Disorder; Disorders of Excessive Somnolence; Humans; Hyperphagia; Male; Moclo | 1992 |
Clinical pharmacology of reversible MAO-A inhibitors.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Piperidines | 1992 |
Safety of moclobemide in clinical use.
Topics: Benzamides; Depressive Disorder; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1992 |
Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Female; Humans; Male; Middle Aged; Moclobemi | 1992 |
Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzamides; Depressive Disorder; Humans; Male; Middle | 1991 |
Alpha 2-adrenoceptor responsivity in depression: effect of chronic treatment with moclobemide, a selective MAO-A-inhibitor, versus maprotiline.
Topics: Adult; Benzamides; Clonidine; Depressive Disorder; Female; Growth Hormone; Humans; Insulin-Like Grow | 1990 |
Moclobemide (Ro 11-1163) safety in depressed patients.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Follow-Up Studies; Humans; Moclobemide; Mono | 1990 |
[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
Topics: Adult; Anthracenes; Antidepressive Agents; Arousal; Benzamides; Depressive Disorder; Female; Humans; | 1989 |
Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients.
Topics: Adult; Benzamides; Bipolar Disorder; Depressive Disorder; Electroencephalography; Evoked Potentials; | 1989 |
Interaction between moclobemide and oral tyramine in depressed patients.
Topics: Adult; Benzamides; Blood Pressure; Depressive Disorder; Drug Interactions; Female; Heart Rate; Human | 1989 |
Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
Topics: Adult; Amitriptyline; Benzamides; Blood Pressure; Cheese; Depressive Disorder; Drug Interactions; Fe | 1986 |
A case of moclobemide overdose.
Topics: Adult; Benzamides; Depressive Disorder; Female; Humans; Moclobemide | 1988 |
Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
Topics: Adult; Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Female; Humans; Male; | 1987 |
Overdose with moclobemide.
Topics: Adult; Benzamides; Depressive Disorder; Female; Humans; Moclobemide; Monoamine Oxidase Inhibitors; S | 1986 |